Intrinsic Imaging Awarded New Clinical Study to Evaluate Innovative Tumor Imaging Platform

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System,...

Levine Leichtman Capital Partners Sells FlexXray

Levine Leichtman Capital Partners ("LLCP"), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company FlexXray Holdings, LLC ("FlexXray" or...

Intrinsic Imaging, a full-service medical imaging core lab providing comprehensive services in support of clinical trials and medical device trials, announces today the award of a Phase II Clinical Trial to evaluate the ability of a novel imaging platform that assists physicians in distinguishing various malignant tissue types from non-malignant tissue.

Intrinsic Imaging has extensive experience in imaging for medical device development. This trial allows the company to utilize this strength to support development of novel imaging platforms in oncology. Intrinsic Imaging is leading the integration of novel methodologies in evaluating new medical imaging technologies for numerous oncology specific medical devices as well as drug product trials where applicable.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, study management, protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. With its portfolio of five ISO certifications, Intrinsic Imaging has the most comprehensive and sophisticated quality management system in the industry.

Todd Joron, President and COO at Intrinsic Imaging: “Intrinsic Imaging is an industry leader in conducting medical device imaging trials.”  He went on to say, “We are extremely pleased to be a critical partner in this medical device trial and help bring this innovative product closer to market.”

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.